US OptionsDetailed Quotes
PFE250110C27000
- 0.01
- 0.000.00%
15min DelayTrading Jan 10 16:00 ET
0.00High0.00Low
0.00Open0.01Pre Close0 Volume15.45K Open Interest27.00Strike Price0.00Turnover705.17%IV4.04%PremiumJan 10, 2025Expiry Date0.00Intrinsic Value100Multiplier-12DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type0.1021Delta0.8604Gamma2596.00Leverage Ratio-41.1553Theta0.0000Rho264.98Eff Leverage0.0001Vega
Pfizer Stock Discussion
Tomorrow is the XD.
Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, Esperion has positioned itself as an acquisition target for larger pharmaceutical compa...
Alright, im dreaming
Pfizer has completed a secondary offering of 700 million Haleon ordinary shares at 357 pence (approximately $4.36) per share on January 17, 2025. The sale was executed through a block trade agreement with multiple financial institutions including J.P. Morgan Securities, Morgan Stanley, HSBC, and others.
Following the transaction, Pfizer now holds 661,709,764 Haleon ordinary shares, representing approximately 7.3% of Haleon's outstanding shares. This includes 197,228,952 restric...
Full year earnings release on 04 Feb 2025. Waiting for good results
Takeda-backed Ascentage Pharma Group (AAPG) (OTCPK:ASPHF), which is developing treatments for blood cancer, has set terms for a $170M U.S. initial public offering.
In an SEC filing, Ascentage (AAPG) said it plans to offer 7.3M American Depositary Shares, representing 29.3M ordinary shares. While the company didn't disclose a price range, it indicated in its filing fee schedule it was looking to raise around $170M.
The company hopes to list its shares on Nasdaq under the symbol A...
No comment yet